Figure 7. TP53BP2 is inhibited by G9a-mediated histone methylation in trophoblasts. (A) H3K4me1, H3K4me2, H3K4me3, H3K9me2, H3K9me3, H3K27me3 and H3K36me3 modifications were detected in the TP53BP2 promoter region. (B) ChIP assays were conducted to assess the enrichment of H3K4me1, H3K4me2, H3K4me3, H3K9me2, H3K9me3, H3K27me3 and H3K36me3 at the TP53BP2 promoter in HTR8/SVneo cells under hypoxia. (C) Immunofluorescence staining was used to detect the expression of H3K9me2 (green) in trophoblasts of the placenta. Scale bar=50 µm. (D, E) The mRNA expression levels of LSD1, SUV39H1, SUV39H2 and G9a were measured via qRT‒PCR in placentas and in HTR8/SVneo cells under hypoxia. (F) The transcriptional activity of the TP53BP2 promoter in HTR8/SVneo cells transfected with sh-G9a under hypoxia. (G) The expression of TP53BP2 in HTR8/SVneo cells treated with BIX-01294 (a G9a-specific inhibitor) under hypoxia was detected via western blotting. The data are presented as the means ± SDs. *P <0.05,**P <0.01,***P <0.001.